Teva names new medical chief
Teva Pharmaceutical Industries (NYSE:TEVA)...
Seekingalpha · 15h ago
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $280.35, marking a +1.51% move from the previous day.
Zacks · 2d ago
Top Healthcare Stocks for July 2022
These are the healthcare stocks with the best value, fastest growth, and most momentum for July 2022.
Investopedia · 2d ago
Let's See If Vertex Pharmaceuticals Can Push Higher on the Charts
Vertex Pharmaceuticals has been knocking on their 52-week highs and the question is whether prices will continue higher or will this company stall out and perhaps turn lower. Aggressive traders could use available weakness to probe the long side of VRTX. · 4d ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 44% Below Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Vertex Pharmaceuticals...
Simply Wall St. · 5d ago
Major Stock Indexes are Mixed; Health Care Stocks Lead, But These Leaders Break Down
The major stock market indexes are mixed and are trading near or at the lows of the day, with the Nasdaq composite and S&P 500 down from the last hour. The Nasdaq composite is up 0.3% while the S&P 500 is down 0.3%. Harmony Biosciences is up 4.8% and now...
Investor's Business Daily · 06/23 17:35
Why Jim Cramer Prefers Devon Energy Over EOG Resources
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Devon Energy Corporation (NYSE: DVN) over EOG Resources, Inc. (NYSE: EOG) as the former is cheaper.
Benzinga · 06/23 12:36
Dow Jones Off Lows As Fed Chief Powell Minimizes Recession Risks
Stocks are holding onto most of Tuesday's gains, but crude oil and Treasury yields tumbled as Fed chief Jerome Powell testified
Investor's Business Daily · 06/22 13:54
Biotech Stock United Therapeutics Revives Breakout, Retakes Buy Zone
Biotech stock United Therapeutics joins peers Vertex and Harmony Biosciences on the Breakout Stocks Index as it reenters a buy zone.
Investor's Business Daily · 06/21 20:00
Strength Seen in Vertex (VRTX): Can Its 4.8% Jump Turn into More Strength?
Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 06/20 12:32
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.
Benzinga · 06/17 17:31
Vertex Pharmaceuticals (VRTX) Stock Moves -1.01%: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $250.96, moving -1.01% from the previous trading session.
Zacks · 06/16 21:45
5 Healthcare Stocks That Are Bucking the Bear Market
McKesson, Bristol Myers Squibb, Merck, Vertex Pharmaceuticals, and Organon are all sitting on year-to-date gains while broader market has slipped into the red. · 06/15 21:30
Vectrus Shareholders Approve Combination with Vertex; Co. Will Be Renamed V2X, To Trade On NYSE Under Ticker VVX
Vectrus, Inc. (NYSE:VEC) today announced that based on voting results from the Special Meeting of Shareholders held today, Vectrus shareholders voted to approve the combination with Vertex. Following the close of the
Benzinga · 06/15 20:07
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Crispr Therapeutics could have a "functional cure" for two inherited blood diseases, analysts said Monday, but CRSP stock plummeted.
Investor's Business Daily · 06/13 17:50
Crispr falls 12% most since 2020 as rival wins FDA backing for beta thalassemia drug
Swiss gene editing firm, Crispr Therapeutics (NASDAQ:CRSP) lost over 12% on Monday its worst intraday decline since Oct. 2020 after a panel advising the FDA unanimously endorsed a gene therapy candidate
Seekingalpha · 06/13 17:44
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.
Benzinga · 06/13 17:27
Expert Ratings for Vertex Pharmaceuticals
Over the past 3 months, 8 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will t...
Benzinga · 06/13 15:08
Cowen Adjusts Price Target on Vertex Pharmaceuticals to $310 From $305, Keeps Outperform Rating
MT Newswires · 06/13 09:34
Webull provides a variety of real-time VRTX stock news. You can receive the latest news about Vertex Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.